Key clinical point: A history of recent exacerbations didn’t significantly affect the safety or efficacy of aclidinium bromide in patients with moderate to severe COPD and high cardiovascular risk.
Major finding: Risk of major adverse cardiac events with aclidinium treatment was not increased vs placebo, irrespective of whether patients had exacerbations in the prior year (interaction P = .233).
Study details: Subgroup analysis of the phase IV ASCENT-COPD study including 3,530 patients with COPD at high cardiovascular risk.
Disclosures: Dr. Wise provided disclosures related to AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Sunovion, Mylan/Theravance, ContraFect, Pearl, Merck, Verona, Novartis, AbbVie, Syneos, Regeneron, and Kiniksa.
Wise R et al. CHEST 2019. Abstract, doi: 10.1016/j.chest.2019.08.231.